| scholarly article | Q13442814 |
| P2093 | author name string | Konstantinos H Katsanos | |
| Epameinondas V Tsianos | |||
| Dimitrios K Christodoulou | |||
| Fotios S Fousekis | |||
| Vasileios I Theopistos | |||
| P2860 | cites work | Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis | Q24541353 |
| Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine | Q24564758 | ||
| A review of the medical treatment of primary sclerosing cholangitis in the 21st century | Q26771816 | ||
| Therapy of Liver Abscesses | Q26796567 | ||
| Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk | Q26829300 | ||
| Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases | Q26864098 | ||
| Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis | Q27012912 | ||
| Sulfasalazine-induced fulminant hepatic failure | Q28327415 | ||
| Methotrexate, alcohol, and liver damage | Q28365381 | ||
| Mesalamine-induced granulomatous hepatitis | Q28369197 | ||
| Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet | Q28574910 | ||
| Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease | Q32086267 | ||
| Pathogenesis and clinical spectrum of primary sclerosing cholangitis | Q33572623 | ||
| Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease | Q33654733 | ||
| Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record | Q33955217 | ||
| Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. | Q53502601 | ||
| Primary biliary cirrhosis | Q56428273 | ||
| Portomesenteric vein thrombosis in patients with inflammatory bowel disease | Q57643472 | ||
| Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study | Q57752112 | ||
| Incidence and risk factors for gallstones in patients with inflammatory bowel disease: A large case-control study | Q57972003 | ||
| Kinetics of Anti–Hepatitis B Surface Antigen Titers After Hepatitis B Vaccination in Patients With Inflammatory Bowel Disease | Q59509258 | ||
| Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study | Q59509574 | ||
| Ulcerative colitis associated with primary biliary cirrhosis | Q61892601 | ||
| Abnormal Hepatic Biochemistries in Patients With Inflammatory Bowel Disease | Q61989964 | ||
| Exposure to a high total dosage of glucocorticoids produces non-alcoholic steatohepatits. | Q64940092 | ||
| Gallbladder disease in patients with primary sclerosing cholangitis. | Q64996440 | ||
| Liver toxicity does not have to follow methotrexate therapy of patients with rheumatoid arthritis. | Q65000150 | ||
| Colchicine therapy of the renal amyloidosis of ulcerative colitis | Q68326147 | ||
| Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis | Q69942168 | ||
| Primary sclerosing cholangitis | Q72596376 | ||
| Oral budesonide in the treatment of primary sclerosing cholangitis | Q73009511 | ||
| Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center | Q73289944 | ||
| Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy | Q73628374 | ||
| A revised natural history model for primary sclerosing cholangitis | Q74042025 | ||
| Association of primary sclerosing cholangitis, ulcerative colitis and coeliac disease in female siblings | Q74593729 | ||
| [Sonographic diagnosis of a liver abscess caused by an enterohepatic fistula in a patient with Crohn's disease] | Q79530378 | ||
| Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis | Q80032261 | ||
| A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis | Q80883152 | ||
| High lifetime risk of cancer in primary sclerosing cholangitis | Q82625908 | ||
| Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome | Q82690618 | ||
| European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease | Q82963520 | ||
| [Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease] | Q83444905 | ||
| Portal vein thrombosis in inflammatory bowel diseases: a single-center case series | Q83615734 | ||
| The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | Q84235401 | ||
| IgG4-associated ampullitis and cholangiopathy in Crohn's disease | Q84974263 | ||
| Primary sclerosing cholangitis | Q85213558 | ||
| Hepatobiliary manifestations of inflammatory bowel disease | Q87977887 | ||
| Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. | Q33958828 | ||
| Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials | Q33959573 | ||
| Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis | Q34097072 | ||
| Vascular complications of inflammatory bowel disease | Q34165290 | ||
| Vedolizumab as induction and maintenance therapy for ulcerative colitis | Q34365566 | ||
| Vedolizumab as induction and maintenance therapy for Crohn's disease | Q34365574 | ||
| Granulomatous hepatitis secondary to histoplasma infection after treatment with infliximab | Q34399044 | ||
| Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis | Q34524586 | ||
| Ulcerative colitis associated with IgG4 cholangitis: similar features in two HLA identical siblings | Q34992859 | ||
| Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature | Q35101366 | ||
| Budd-Chiari syndrome in a patient with ulcerative colitis and no inherited coagulopathy | Q35174822 | ||
| Cholecystectomy in Patients With Crohn's Ileitis | Q35578926 | ||
| Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population | Q35595032 | ||
| Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines | Q35595076 | ||
| Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis | Q35595146 | ||
| Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? | Q35596373 | ||
| Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis | Q35629109 | ||
| Is gallstone disease associated with inflammatory bowel diseases? A meta-analysis | Q35762293 | ||
| Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis | Q36691549 | ||
| Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review | Q36772955 | ||
| Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature | Q36835627 | ||
| Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease | Q37058852 | ||
| Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. | Q37306085 | ||
| Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. | Q37317444 | ||
| Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease | Q37355530 | ||
| Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease | Q37701805 | ||
| Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease | Q37769185 | ||
| A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease | Q37796190 | ||
| A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. | Q37814549 | ||
| Hepatosplenic T-cell lymphoma and inflammatory bowel disease | Q37814566 | ||
| Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease | Q37832839 | ||
| Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis | Q37847100 | ||
| Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis | Q37866339 | ||
| Granulomatous liver disease | Q38006147 | ||
| Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review | Q38057474 | ||
| The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease | Q38062336 | ||
| Extraintestinal manifestations and complications in IBD. | Q38120146 | ||
| Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis | Q38166551 | ||
| Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. | Q38210793 | ||
| Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis | Q38356761 | ||
| Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease | Q38358419 | ||
| Toxicity and response to thiopurines in patients with inflammatory bowel disease | Q38443981 | ||
| The natural history of small-duct primary sclerosing cholangitis | Q38457100 | ||
| Hepatic manifestations of inflammatory bowel diseases | Q38814158 | ||
| Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis | Q38919832 | ||
| Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees | Q39041427 | ||
| Liver abscess in Crohn's disease. Report of four cases and review of the literature | Q39793649 | ||
| Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma. | Q40006105 | ||
| Liver abscesses as a complication of Crohn's disease | Q40502988 | ||
| Pyogenic liver abscess in patients with inflammatory bowel disease: a nationwide cohort study | Q40900464 | ||
| Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD. | Q40989271 | ||
| New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease | Q41256627 | ||
| Familial occurrence of primary sclerosing cholangitis and ulcerative colitis | Q41587039 | ||
| Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro | Q41901439 | ||
| Liver disorders in inflammatory bowel disease | Q42122089 | ||
| The Use of ERCP Versus MRCP in Primary Sclerosing Cholangitis. | Q42150493 | ||
| Reversible Sulfasalazine-Induced Granulomatous Hepatitis | Q42241209 | ||
| Genetic epidemiology of primary sclerosing cholangitis | Q42909560 | ||
| Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. | Q42997987 | ||
| Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis | Q43433946 | ||
| Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis | Q43568613 | ||
| Ileal pouch-anal anastomosis and liver transplantation for ulcerative colitis complicated by primary sclerosing cholangitis | Q43637205 | ||
| Veno-occlusive disease (VOD) in Crohn's disease (CD) treated with azathioprine | Q44553019 | ||
| Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis | Q44669455 | ||
| Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease | Q44797986 | ||
| Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study | Q45001248 | ||
| Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis | Q45103515 | ||
| Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. | Q45812205 | ||
| Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome | Q46572197 | ||
| 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension | Q46982269 | ||
| Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis | Q47862595 | ||
| Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial | Q48419903 | ||
| Presence of concomitant inflammatory bowel disease is associated with an increased risk of postcholecystectomy complications | Q50155738 | ||
| Gallstones and their composition in patients with ileoanal anastomosis | Q50173876 | ||
| Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy | Q50217361 | ||
| Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. | Q50491235 | ||
| Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. | Q50628941 | ||
| No evidence for abnormal gallbladder emptying in Crohn's disease. | Q50997588 | ||
| A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. | Q51360974 | ||
| Bile composition in patients with ileal resection due to Crohn's disease. | Q51569951 | ||
| Diagnosis and management of primary sclerosing cholangitis. | Q51726466 | ||
| P433 | issue | 2 | |
| P921 | main subject | inflammation | Q101991 |
| inflammatory bowel diseases | Q917447 | ||
| P304 | page(s) | 83-94 | |
| P577 | publication date | 2018-04-07 | |
| P1433 | published in | Gastroenterology research | Q27723942 |
| P1476 | title | Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. | |
| P478 | volume | 11 |
| Q64262341 | The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults | cites work | P2860 |
Search more.